Graft-vs-Host disease treatment gets boost

The European Medicines Agency (EMA) has granted Israeli biotech Enlivex “orphan” status for its ApoCell treatment to prevent Graft-vs-Host Disease.  It will speed up development of the Israeli innovation that stops rejection of transplanted cells and bone marrow.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *